Investment Rating - The report maintains a "BUY" rating for Kelun-Biotech, indicating a potential return of over 15% over the next 12 months [3][14]. Core Insights - Kelun-Biotech is transitioning from a clinical-stage biotech to a biopharmaceutical company, with 2025 marked as its inaugural year of commercialization, supported by four approved products and a strong revenue trajectory [1]. - The company reported total revenue of RMB2.06 billion in 2025, reflecting a year-on-year growth of 6.5%, with pharmaceutical product sales contributing RMB543 million [1][2]. - The inclusion of three core assets (Sac-TMT, A167, and A140) in the National Reimbursement Drug List (NRDL) effective January 2026 is expected to drive volume growth in 2026 [1]. - Despite a widened net loss of RMB382 million in 2025, the company's financial position remains robust, with RMB4.6 billion in cash and financial assets as of the end of 2025 [1]. Financial Summary - Revenue projections for FY26E are RMB2.127 billion, with expected growth of 3.4% year-on-year, and projected revenue for FY28E is RMB5.866 billion, reflecting a significant growth of 113.6% [2][11]. - The net profit is projected to be a loss of RMB689.7 million in FY26E, improving to a profit of RMB703.6 million by FY28E [2][11]. - The report indicates a gross profit margin improvement from 71.9% in FY25A to 81.6% in FY28E [12]. Share Performance and Valuation - The target price for Kelun-Biotech is set at HK$507.11, representing a 20.5% upside from the current price of HK$421.00 [3]. - The market capitalization of the company is approximately HK$98.17 billion [3]. - The DCF valuation per share is estimated at RMB446.25, equivalent to HK$507.11, based on a WACC of 8.69% and a terminal growth rate of 3.5% [7].

Core Viewpoint - The company, Kelun-Botai, is a leading player in the ADC (Antibody-Drug Conjugate) sector, with a robust technology platform and significant backing from multinational corporations (MNCs) [1] Group 1: Company Overview - Kelun-Botai was established in 2016 as an innovative R&D subsidiary of Kelun Pharmaceutical, focusing on three major technology platforms: ADC, macromolecules, and small molecules [1] - As of the 2024 annual report, Kelun-Botai has over 30 innovative assets and more than 10 drugs in clinical stages, indicating a well-structured pipeline [1] - The company is expected to enter a rapid growth phase in 2025, with promising commercial progress anticipated [1] Group 2: ADC Platform Development - The ADC platform focuses on both oncology and non-oncology development strategies, with research capabilities endorsed by MNCs [1] - SKB264, an optimized drug based on trastuzumab, has a comprehensive layout for breast cancer and non-small cell lung cancer (NSCLC), with multiple approvals and submissions expected between 2024 and 2025 [2] - A166 has reached critical endpoints in phase II trials for advanced HER2+ breast cancer and is expected to receive approval in 2025 [2] - The early ADC pipeline includes various targets such as CLDN18.2 and Nectin-4, with new products like SKB571 and SKB107 anticipated to follow [2] Group 3: Non-ADC Platform Development - The non-ADC platform is entering a harvest phase, covering oncology and autoimmune fields [2] - A167 (PD-L1) has received approvals for multiple indications, while A140 (a biosimilar of cetuximab) is also set for approval in early 2025 [2] - A400, a selective RET inhibitor for RET+ NSCLC, is expected to submit for market approval within the year [2] Group 4: Financial Projections - Revenue forecasts for the company from 2025 to 2027 are projected at 2.006 billion, 2.884 billion, and 4.696 billion yuan, reflecting year-on-year growth rates of 3.8%, 43.8%, and 62.8% respectively [3] - The current stock price corresponds to price-to-sales (PS) ratios of 34.7x, 24.2x, and 14.8x for the respective years [3] - The company is expected to reach a commercialization inflection point in 2025, with numerous catalysts from clinical data and business development expectations [3]